How to Buy Abbott Laboratories Stock
Abbott Laboratories
Abbott Laboratories is a medical device company located in Illinois, United States, which is part of the Healthcare sector, and is traded under the ticker ABT on the NYSE exchange.
Abbott Laboratories stock last closed at $130.98, up 0.99% from the previous day, and has increased 23.68% in one year. It has overperformed other stocks in the Medical Devices industry by 0.42 percentage points. Abbott Laboratories stock is currently +31.36% from its 52-week low of $99.71, and -7.26% from its 52-week high of $141.23.
There are currently 1.73B shares of ABT outstanding. The market cap of ABT is $227.16B. In the past 24 hours, 10.47M ABT shares were traded.
How to Buy Abbott Laboratories Stock
Not sure how to invest in Abbott Laboratories stock? Here's how.
- Figure out where to buy Abbott Laboratories stock: You need to choose a stock brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you figure out where to buy Abbott Laboratories stock.
- Sign up for your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Deposit funds into your investment account: Select your method of payment and add your info.
- Analyze Abbott Laboratories stock: The Abbott Laboratories ticker symbol is ABT. Is Abbott Laboratories stock a good investment? Should you buy shares of ABT? How do ABT's underlying business fundamentals look? Do top analysts think Abbott Laboratories is a good buy? Why has ABT's stock price moved recently? (Hint: Our stock market research tools can help you understand if ABT is a good stock to buy).
- Execute your ABT buy order: Decide if you will purchase ABT shares at the current market price or use a limit order to buy ABT stock at a particular price.
- Get key alerts regarding your ABT investment: Create a watchlist to key updates about your position in Abbott Laboratories shares.
Step 1: Figure out where to buy Abbott Laboratories stock
You will need a brokerage account to access the NYSE market and buy ABT shares.
Our recommended brokerage: eToro
In our opinion, eToro is the best place to buy stocks. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to global markets: From Technology to Real Estate, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've selected your brokerage, you'll need to fill out some personal details so you are able to invest in ABT stock today.
How to Set Up a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to open your new brokerage account.
- Send your info by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have created your account on our top ranked stock market app, you can securely and quickly fund your account:
Watch the walkthrough below for more details transferring money into your brokerage account.
Step 4: Analyze Abbott Laboratories stock
After you have selected the best place to buy Abbott Laboratories stock, it's important to research their stock prior to investing, so you truly understand the risk as well as the opportunity.
Overview of key ABT info
Abbott Laboratories Overview
WallStreetZen was built to help part-time investors do more in-depth fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on ABT's stock page.
What is the fair value of ABT stock?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge ABT's fair value.
Using relative valuations metrics:
- ABT may be undervalued based on its P/E ratio of 17.08x, relative to Medical Devices industry P/E ratio of 41.14x
- ABT could be overvalued based on its P/B ratio of 4.74x, relative to Medical Devices industry P/B ratio of 3.8x
You can access more valuation research on ABT's stock here.
ABT Financial Overview
Signs that ABT is financially healthy:
- There are more short-term assets than long-term liabilities on the ABT balance sheet.
- ABT earnings of $7.57B is not enough to cover its interest payments.
- ABT's operating cash flow of $8.56B allows it to safely service it's debt of $14.13B.
- Total ABT debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the ABT balance sheet.
- ABT profit margin has gone up from 14.3% to 31.9% in the past year.
Signs that ABT is not financially healthy:
- ABT has a relatively high debt to equity ratio of 0.7.
Is ABT stock a Buy, Hold, or Sell, according to analysts?
Out of 12 Equities analysts who track ABT, the consensus analyst rating on ABT is a Strong Buy
Please note that analyst ratings are not stock recommendations, nor are they financial advice.
Most Recent ABT Analyst Recommendations
Matt Miksic, a bottom 6% analyst from Barclays maintains ABT with a strong buy rating and raises their ABT price target from $158.00 to $159.00, on Apr 17, 2025.
Rick Wise, a top 8% analyst from Stifel Nicolaus maintains ABT with a strong buy rating and raises their ABT price target from $135.00 to $145.00, on Apr 17, 2025.
Stifel Nicolaus's Rick Wise raised their price target on Abbott Laboratories (NYSE: ABT) by 7.4% from $135 to $145 on 2025/04/17. The analyst maintained their Strong Buy rating on the stock.
Abbott Laboratories reported its Q1 2025 earnings on 2025/04/16.
Amid broad macroeconomic uncertainty, factors that put the company squarely in the "quality growth" category, according to Wise, include:
- Abbott Laboratories' solid Q1 performance.
- Management's restated FY 2025 guidance.
- An upbeat remark about perhaps an increasing outlook, aside from tariff challenges.
Earnings Report
For Q1 2025, Abbott Laboratories reported:
- EPS of $1.09, which beat the Zacks Consensus Estimate of $1.07 and Q1 2024's $0.98.
- Revenue of $10.36B, which missed the Zacks Consensus Estimate by 0.56% but beat Q1 2024's $9.96B.
Management guided:
For Q2 2025:
- EPS of 1.23 to $1.27.
For FY 2025:
- EPS of $5.05 to $5.25.
- 7.5% to 8.5% organic revenue growth.
Chairman & CEO Robert B. Ford commented: "Once again, Abbott's diversified business model delivered top-tier sales and EPS growth.
"It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth."
Matthew Taylor, a top 11% analyst from Jefferies maintains ABT with a hold rating and raises their ABT price target from $135.00 to $137.00, on Apr 17, 2025.
Travis Steed, a top 26% analyst from Bank of America maintains ABT with a strong buy rating and raises their ABT price target from $133.00 to $150.00, on Mar 10, 2025.
Joanne Wuensch, a top 6% analyst from Citigroup maintains ABT with a strong buy rating and raises their ABT price target from $135.00 to $160.00, on Mar 4, 2025.
You can dig deeper into what analysts are forecasting on the Abbott Laboratories stock forecast page.
ABT Momentum
ABT Growth Metrics
Last year, ABT earnings were $13.40B. During the last five year, ABT's earnings have gone up by 29.95% per year. This was faster than the Medical Devices industry average of 10.26%.
Last year, ABT revenue was $41.95B. Over the last five year, ABT's revenue has grown by 5.63% per year. This was slower than the Medical Devices industry average of 9.92%.
You can analyze ABT's earnings and revenue performance here.
Are ABT insiders buying or selling the stock?
In the last 12 months, insiders at ABT have sold more shares than they have bought.
Lisa D. Earnhardt, EVP AND GROUP PRESIDENT of ABT, was the latest ABT insider to buy. They bought $16,196.00 worth of ABT shares on Mar 7, 2025.
Learn more about who owns ABT stock here.
Can I rely on ABT as an income stream?
No, Abbott Laboratories doesn't provide an income stream by paying out dividends.
ABT Social Trading Data
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Execute your ABT buy order
You have two main options:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are usually the best for newer investors. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at a specific dollar amount, place a limit order.
Hit the Open Trade button and your broker will execute your order.
If you need more help investing in stocks on eToro, click the how to video below:
Step 6: Get key alerts regarding your ABT investment
Now that you own some shares in ABT, you'll want to keep up with your new stock purchase.
Put ABT on a watchlist to keep tabs on your ABT stock.
ABT Feed
How to Buy Stock in Abbott Laboratories
To reiterate, here are the 6 steps to buy Abbott Laboratories stock:
- Figure out where to buy Abbott Laboratories stock
- Sign up for your brokerage account
- Deposit funds into your investment account
- Analyze Abbott Laboratories stock
- Execute your ABT buy order
- Get key alerts regarding your ABT investment
If you are looking for a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you would like to keep tabs on your new investment in Abbott Laboratories, get started below.
More Articles You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.